Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Anti‐Amyloid Immunotherapy for AD: A Potential Link between ARIA and Complement

1 Dec 2024

Abstract excerpt

Abstract Background Anti‐amyloid antibodies have been associated with amyloid‐related‐imaging‐abnormalities (ARIA) in AD patients, causing vasogenic edema and microhemorrhages, especially in ApoE4 carriers. Here, we compared recombinant 3D6‐L, a murine version of bapineuzumab, and an isotype control IgG2a monoclonal antibody (mAb) to investigate potential mechanisms, including complement activation, involved in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alzheimer's disease research and treatments
Share to Intracerebral and Subarachnoid Hemorrhage Research
Share to Neuroinflammation and Neurodegeneration Mechanisms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39751298
DOI: 10.1002/alz.093183

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Anti‐Amyloid Immunotherapy for AD: A Potential Link between ARIA and ComplementPMID 39751298Read ↗

Early Binding of Anti-Amyloid Antibodies to CAA Drives Complement Activation, Inflammation and ARIA in MiceSemantic proximity Read ↗

Anti-amyloid immunotherapy drives APOE4 specific increases in glial reactivity, perivascular immune activation, and ARIA-like eventsSemantic proximity Read ↗

Intravenous anti-Aβ immunotherapy acutely increases cerebral amyloid angiopathy and vascular damages in APOE4 miceSemantic proximity Read ↗

Complement-Mediated Events in Alzheimer’s Disease: Mechanisms and Potential Therapeutic TargetsSemantic proximity Read ↗

ScFv-h3D6 Prevents Bapineuzumab-Induced Hemorrhagic Events in the APP23 Mouse Model of Alzheimer’s DiseaseSemantic proximity Read ↗

Development of the clinical candidate PBD-C06, a humanized pGlu3-Aβ-specific antibody against Alzheimer's disease with reduced complement activation.Semantic proximity Read ↗

C5aR1 antagonism alters microglial polarization and mitigates disease progression in a mouse model of Alzheimer’s diseaseSemantic proximity Read ↗

FDA-Approved Passive Immunization Treatments Against Aβ in Alzheimer’s Disease: Where Are We Now?Semantic proximity Read ↗

Distinct serum anti-Aβ antibody patterns in hemorrhagic and inflammatory cerebral amyloid angiopathy manifestationsSemantic proximity Read ↗

Chronic Verubecestat Treatment Suppresses Amyloid Accumulation in Advanced Aged Tg2576-AβPPswe Mice Without Inducing Microhemorrhage.Semantic proximity Read ↗

Vascular alterations in PDAPP mice after anti-Aβ immunotherapy: Implications for amyloid-related imaging abnormalities.Semantic proximity Read ↗

An effector-reduced anti-β-amyloid (Aβ) antibody with unique aβ binding properties promotes neuroprotection and glial engulfment of Aβ.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.